RESEARCH ARTICLE

The Human dsRNA binding protein PACT is unable to functionally substitute for the *Drosophila* dsRNA binding protein R2D2 [version 1; peer review: 2 approved]

Benjamin K Dickerman^{1,2}, Jocelyn A McDonald¹, Ganes C Sen¹

¹Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA

²Department of Microbiology and Immunology, University of Melbourne, Parkville, 3010, Australia

V1 First published: 18 Oct 2013, 2:220
<https://doi.org/10.12688/f1000research.2-220.v1>

Latest published: 28 Mar 2014, 2:220
<https://doi.org/10.12688/f1000research.2-220.v2>

Abstract

The primary function of the dsRNA binding protein (dsRBP) PACT/RAX is to activate the dsRNA dependent protein kinase PKR in response to stress signals. Additionally, it has been identified as a component of the small RNA processing pathway. A role for PACT/RAX in this pathway represents an important interplay between two modes of post-transcriptional gene regulation. The function of PACT/RAX in this context is poorly understood. Thus, additional models are required to clarify the mechanism by which PACT/RAX functions. In this study, *Drosophila melanogaster* was employed to identify functionally orthologous dsRNA-binding proteins. Transgenic *Drosophila* expressing human PACT were generated to determine whether PACT is capable of functionally substituting for the *Drosophila* dsRBP R2D2, which has a well-defined role in small RNA biogenesis. Results presented here indicate that PACT is unable to substitute for R2D2 at the whole organism level.

Open Peer Review

Approval Status

	1	2
version 2 (revision) 28 Mar 2014
version 1 18 Oct 2013	view	view
1. Anthony Sadler , Monash University, Melbourne, Australia		
2. Anita Corbett , Emory University, Atlanta, GA, USA		

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Ganes C Sen (seng@ccf.org)

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by NIH grant CA062220, awarded to G. Sen.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2013 Dickerman BK *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Dickerman BK, McDonald JA and Sen GC. **The Human dsRNA binding protein PACT is unable to functionally substitute for the *Drosophila* dsRNA binding protein R2D2 [version 1; peer review: 2 approved]** F1000Research 2013, 2:220 <https://doi.org/10.12688/f1000research.2-220.v1>

First published: 18 Oct 2013, 2:220 <https://doi.org/10.12688/f1000research.2-220.v1>

Introduction

The dsRNA binding protein (dsRBP) PACT (referred to as RAX in the mouse) activates the dsRNA dependent protein kinase PKR in response to various stress signals^{1–5}. This in turn results in repression of translation through phosphorylation of the eukaryotic translation initiation factor eIF2 α ⁶. Although the biochemical function of PACT/RAX as an activator of PKR is well established, the physiological role of this protein *in vivo* is unclear. Indeed, generation of mice lacking RAX revealed a role for this protein in craniofacial^{7,8} and anterior pituitary development⁹ that is not readily explained by current knowledge of its biochemical function. More recently, PACT/RAX has been identified as a component of the RNA silencing (siRNA/miRNA) pathway^{10,11}, although a detailed understanding of its role in this pathway is limited. Thus, PACT/RAX functions in two independent pathways that govern post-transcriptional gene regulation and as such it is important to understand the overall physiological function of this protein.

RNA silencing through the micro-RNA (miRNA) and short-interfering RNA (siRNA) pathways regulates nearly every aspect of cellular biology (reviewed by van Kouwenhove *et al.*^{12,13}). Both siRNA and miRNA pathways require cytoplasmic processing of precursor molecules (either dsRNA or ~70bp pre-miRNAs) to generate mature guide RNAs (reviewed by van Kouwenhove *et al.*¹²). In both cases, this cytoplasmic processing step is accomplished by the endonuclease Dicer in complex with one or more dsRNA binding proteins, which cleaves precursor RNA molecules into ~20–25bp dsRNA. One of the two strands of the Dicer-processed mature RNA molecule (known as the guide strand) is then loaded into the effector complex, the RNA-induced silencing complex (RISC) (reviewed by Czech and Hannon¹³). Although the precise composition of the RISC is unclear, various studies have demonstrated the presence of a mature guide RNA, Dicer, one or more accessory dsRBPs, and one of the four members of the Argonaute protein family (Ago1–4) which function as the effector enzymes in the terminal silencing step¹⁴.

The RNA silencing pathways of metazoans have largely been investigated in the model organisms *Caenorhabditis elegans* and *Drosophila melanogaster*. In both systems, it was discovered that the endonucleases required for cleavage of pri-miRNAs (Drosha) and pre-miRNAs/siRNA precursors (Dicer) form complexes with specific dsRBPs. These proteins, like PACT/RAX, are comprised of tandem dsRBDs with no other identifiable domains (Drosha complexes with Pasha/DGCR8¹⁵, *C. elegans* Dicer binds RDE-4¹⁶, *D. melanogaster* Dicer-1 binds Loquacious (LOQS)¹⁷ and *D. melanogaster* Dicer-2 binds R2D2¹⁸). Furthermore, these dsRBPs are required for the processing functions of the complexes. In mammalian systems, processing of both siRNA and miRNA is performed by a common Dicer enzyme. Both PACT/RAX and a similar dsRBP Tat Trans-activation element RNA binding protein (TRBP) in human/Protamine-1 RNA binding protein (PRBP) in mouse have been demonstrated to bind Dicer through either their N-terminal dsRNA binding motifs or their C-terminal Merlin-Dicer-PACT Liaison (Medipal) domain (which contains the PKR activation domain of PACT/RAX)^{10,11,19}. The binding of PACT, TRBP or both with Dicer enhances the ability of Dicer to process dsRNA into siRNAs *in vitro*¹⁰. These findings suggest a functional significance to the PACT/TRBP/Dicer interactions, although the mechanism by which this occurs is unclear. These reports

suggest that in addition to the regulating PKR activation, PACT/RAX may affect post-transcriptional control via small RNA pathways.

In *Drosophila*, processing of small RNA precursors is accomplished by separate enzymes, Dicer-1 for miRNA and Dicer-2 for siRNA²⁰. The dsRNA binding proteins LOQS¹⁷ and R2D2¹⁸ bind Dicer-1 to Dicer-2 respectively. LOQS encodes four isoforms; LOQS-PA and LOQS-PB contain three tandem dsRBDs whereas both LOQS-PC and LOQS-PD^{21,22} lack the third C-terminal dsRBD. R2D2 encodes a single isoform that is comprised of two dsRBDs¹⁸ (Figure 1). LOQS and R2D2 sort precursor RNA molecules based on the presence or absence of mismatches in the stemloop of the hairpin or dsRNA precursor to the appropriate Dicer processing pathway²³ and facilitate RISC loading^{24,25}. Within dsRBDs there is a high degree of sequence similarity (71–78% similarity, see Table 1) between PACT and LOQS PA and PB (which have all three dsRBDs in common). This sequence similarity coupled with the tandem dsRBD architecture (see Figure 1 and Table 1) indicates potential functional orthology between PACT and LOQS. Although R2D2 is significantly less similar to PACT (46% sequence similarity within dsRBD2, with no detectable similarity within dsRBD1), it has nonetheless been demonstrated to bind Dicer-2¹⁸ and possesses a tandem dsRBD architecture similar to PACT and LOQS and thus may also function orthologously to PACT/RAX.

Previous studies have produced mutant *D. melanogaster* lines lacking either of the dsRBPs that interact with Dicer-1 and Dicer-2. Flies deficient in all four isoforms of LOQS display developmental lethality, and do not survive past the pupal stage²⁶. In contrast, flies homozygous mutant for a null allele of *r2d2* are semi-lethal but the surviving flies have severe fertility defects²⁷. The fertility phenotype results from defective oogenesis. Specifically, loss of R2D2 disrupts formation of the stalk cells, which normally separate individual follicles from each other²⁸. This phenotype is enhanced by a *dicer-1* mutant, indicating an unexpected interaction between R2D2 and Dicer-1 rather than Dicer-2²⁷.

We hypothesized that one or more dsRNA binding proteins with known function in *D. melanogaster* are functionally orthologous to PACT/RAX, and that identification of the functional ortholog(s) would provide insight into the small RNA processing function of PACT/RAX. We sought to identify proteins orthologous to PACT/RAX by transgenically expressing human PACT in the well-characterized *Drosophila* genetic model system. We report here our efforts to determine the degree to which human PACT is a functional ortholog of *Drosophila* R2D2.

Materials and methods

Cell lines, plasmids and antibodies

HeLa cells (ATCC CCL-2) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing glucose (4.5g/L), penicillin (50U/ml), streptomycin (50 μ g/ml), L-glutamine (2mM) and sodium pyruvate (1mM) (Cleveland Clinic Lerner Research Institute Media Preparation Core) supplemented with 10% fetal bovine serum (Atlanta Biologicals) at 37°C in 5% CO₂. The pUASP vector was obtained from [Drosophila Genomics Resource Center](#). A polyclonal rabbit antibody raised against full length PACT (produced in-house)²⁹ was used at 1:8000 and was detected using 1:10000

Figure 1. Schematic Representation of PACT and *Drosophila* dsRBPs. Schematic diagram of the PACT, LOQS and R2D2 proteins depicting the organization of their dsRBD domains. Dashed lines designate dsRBD1, 2 or 3.

horseradish peroxidase (HRP) conjugated polyclonal goat anti-rabbit secondary (Rockland Immunochemicals # 611-103-122).

Generation of pUASP plasmids

To obtain PACT cDNA, total RNA was extracted from HeLa cells using Trizol (Invitrogen) according to the manufacturer’s instructions, followed by DNase treatment using the DNA-free kit (Ambion). Extracted, DNase-treated RNA was then reverse transcribed with the Superscript III system (Invitrogen) using random hexamers. The resulting cDNA was used to amplify the coding sequence of PACT by PCR using the primers 5’BamHI-PACT(UAS) (AAG GAT CCA AAC ATG TCC CAG AGC AGG CAC C) and 3’XbaI-PACT (GGC GGA TCC TTA CTT TCT TTC TGC TAT TAT CTT TAA ATA C). The resulting product was digested with BamHI (New England Biolabs Inc. #R0136) and XbaI (New England Biolabs Inc. #R0145) and

ligated into pUASP to generate pUASP-PACT. The full-length *Drosophila* *r2d2* cDNA was amplified by PCR from a plasmid obtained from *Drosophila* Genome Research Center (cDNA #LD06392) using 5’BamHI-R2D2(UAS) (AAG GAT CCA AAC ATG GAT AAC AAG TCA GCC GTA TC) and 3’XbaI-R2D2 (AAA TCT AGA TTA AAT CAA CAT GGT GCG AAA ATA GTC TAT TAT ATG G). The resulting product was digested with BamHI and XbaI and ligated into pUASP to generate pUASP-R2D2. Final cloned plasmids were sequence verified using the primers listed above by the Cleveland Clinic Lerner Research Institute Genomics Core.

Protein isolation and western blot

Protein was isolated by homogenizing individual adult flies in Triton X-100 lysis buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 1% Triton X-100, 1mM EDTA, 5mM 2-mercaptoethanol, 10%

Table 1. Amino acid sequence similarity between PACT and *Drosophila* dsRBPs. Amino acid sequence identity and similarity (positives) between dsRNA binding domains of PACT and the *Drosophila* dsRNA binding proteins determined by BLAST (blastp) alignment; ~ indicates no detectable similarity. The three dsRBDs shown for LOQS correspond to the shared dsRBDs of PA and PB isoforms; the PC and PD isoforms share the first and second but lack the third dsRBD.

		PACT dsRBD1		PACT dsRBD2		PACT dsRBD3	
		Identity	Similarity	Identity	Similarity	Identity	Similarity
LOQS	dsRBD1	55%	71%	~	~	~	~
	dsRBD2	~	~	62%	78%	~	~
	dsRBD3	~	~	~	~	57%	76%
R2D2	dsRBD1	~	~	~	~	~	~
	dsRBD2	~	~	26%	46%	~	~

glycerol, supplemented with Complete protease inhibitor and PhoSTOP (Roche)). Protein was separated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane (Immobilon, Millipore) for western blot analysis. Western blots were visualized using enhanced chemiluminescence (ECL) detection reagents (GE Healthcare Lifesciences #RPN2106).

Drosophila strains and genetics

Flies were maintained and crossed at 25°C according to standard protocols³⁰. Fly food was prepared according to the [standard recipe](#) from Bloomington *Drosophila* Stock Center with minor modifications (83.3ml/L molasses, 33.75g/L yeast, 97.58g/L cornmeal, 31g/L agar, 15.67ml/L Tegosept, all purchased from Genesee Scientific). Transgenic UAS-*PACT* and UAS-*r2d2* flies were generated³¹ by Model Systems Genomics (Duke University, Durham, NC) using the plasmids pUASP-*PACT* and pUASP-R2D2 described above. The following fly strains were obtained from the [Bloomington Drosophila Stock Center](#): *w¹¹¹⁸*, *r2d2¹/CyO* (a null allele;²⁷) and *Df(2L)BSC142/CyO*. Tubulin (*tub*)-*GAL4* (insert on X) was a gift of Dr. A. Page-McCaw. Homozygous viable *r2d2¹* flies were only obtained infrequently, suggesting that the stock acquired a second-site lethal mutation. Therefore, all experiments were performed by outcrossing *r2d2¹* to the deficiency *Df(2L)BSC142* (deletion of 28C3; 28D3, including the *r2d2* gene at 28C4). Standard genetic methods were used to construct the following genotypes:¹ *tub-Gal4*; *r2d2¹/CyO*; ² *Df(2L)BSC142/CyO*; UAS-*PACT*; and ³ *Df(2L)BSC142/CyO*; UAS-*r2d2*.

Egg collection and hatch rate determination

Females of the genotype *tub-GAL4*; *r2d2¹/Df(2L)BSC142*; +/UAS-*x* (where *x* is *PACT* or *r2d2*) were outcrossed with *w¹¹¹⁸* males for fertility tests. Crosses to test fertility were established in vials of food for 24 hours prior to transferring flies to an egg collection chamber. Females were allowed to lay eggs on grape juice agar plates (Genesee Scientific, #47-102) for 1 hr prior to collecting the plate, and incubating at 25°C for 24 hours to allow eggs to hatch. The total number of eggs laid was determined by counting the number of larvae and the number of unhatched eggs. Hatch rate was calculated as the number of larvae divided by the number of total eggs laid. Student's t-test of two independent experiments (defining *P* < 0.05 as statistically significant) was performed using Graphpad Prism version 6.02 software package (Graphpad Software).

Results

Generation of human *PACT*-expressing transgenic *Drosophila melanogaster*

We reasoned that the genetically tractable *Drosophila* model system could be used to study the *in vivo* functions of *PACT*. Because there is no known PKR ortholog in *Drosophila*, this also allows the role of *PACT* in small RNA processing to be investigated independent of PKR activation. Moreover, the well-characterized siRNA and miRNA processing pathways and availability of *logs* and *r2d2* mutant alleles make this an attractive system to study the role of *PACT* in the small RNA pathways. Various human proteins have been used to rescue *Drosophila* mutant phenotypes in order to identify homologous and orthologous proteins^{32–34}, therefore to identify proteins orthologous to *PACT*, a human *PACT* transgene was constructed

and introduced into *Drosophila*. This transgenic line was used to determine whether *PACT* can substitute for *Drosophila* dsRNA binding proteins that regulate small RNA processing (see below).

Human *PACT*-expressing *D. melanogaster* were created using the Gal4-UAS bipartite expression system³⁵. This system allows the generation of flies containing transgenes of interest under the transcriptional control of the UAS element. These lines then can be crossed to a number of Gal4-driver flies to tailor transgene expression to the needs of a specific experiment. The full-length coding region of the Human *PACT* gene was cloned into the pUASP vector under the transcriptional control of the UASp element, a modified form of UAS that permits expression in both somatic and germline cells³⁶. Several UAS-*PACT* transformants were obtained and their chromosomal insertions mapped. A stock that carried an insert on chromosome 3 was retained and crossed to the ubiquitous *tub-GAL4* driver.

We next tested whether Human *PACT* was expressed at detectable levels *in vivo*. Flies expressing *tub-Gal4* alone, containing the UAS-*PACT* transgene alone, and flies with *tub-Gal4* driving UAS-*PACT* were analyzed by western blot for *PACT* expression in whole flies. Using an antibody that recognizes Human *PACT*²⁹, we detected a protein band of the expected size (~34 kDa) in *tub-GAL4*; UAS-*PACT* flies but not in the individual parental lines (Figure 2). Importantly, because we obtained viable *tub-GAL4*; UAS-*PACT* adult flies, this experiment also demonstrates that ubiquitous transgenic expression of *PACT* does not impair *Drosophila* development.

Figure 2. Expression of human *PACT* in transgenic *Drosophila*. Western blot analysis of total protein isolated from whole flies of the indicated genotypes. Flies carrying both the *tub-Gal4* and UAS-*PACT* elements show a protein band of expected size for *PACT* that is not present in either stock alone; a non-specific band is indicated (*). Arrow denotes predicted molecular weight of Human *PACT* (34 kDa). Additional bands of smaller size likely represent degradation products.

Figure 3. Rescue of the R2D2 deficient fertility defect by transgenic expression of R2D2 but not human PACT. (A) Schematic representation of the experimental cross used to test fertility. UAS-x refers to the transgene shown in (B) and (C), for control crosses with no transgene the genotype Df(2L)BSC142/CyO; UAS-x was replaced with Df(2L)BSC142/CyO. (B) Calculated hatch rate of eggs produced by wild-type (w^{1118}) flies, flies with one copy of $r2d2$ (+/-; either $r2d2^1/\text{CyO}$ or Df(2L)BSC142/CyO) and flies lacking both copies of $r2d2$ (-/-, $r2d2^1/\text{Df}(2\text{L})\text{BSC142}$) and either expressing no UAS-transgene or expressing UAS-PACT or UAS- $r2d2$; these flies were outcrossed to w^{1118} males for the fertility tests. (C) Total number of eggs laid from the crosses depicted in (B). Graphs show mean $\pm$ SEM of two independent experiments, p-values were calculated by Student's t-test.

Expression of human PACT is insufficient to overcome the *Drosophila* R2D2 deficient phenotype

The focus of the work presented here is on PACT rescue of the *r2d2* loss-of-function mutant phenotype. Investigation of the functional substitution between human PACT and *Drosophila* LOQS was investigated in a separate project in our lab and will be reported elsewhere.

Flies mutant for *r2d2* have reduced fertility²⁷. Therefore, we sought to determine the extent to which PACT can suppress *r2d2* mutant fertility defects. We performed fertility tests using a standard egg-laying and hatching assay. Crosses were performed to obtain female progeny that carried the *r2d2*¹ allele over a deficiency that removes the *r2d2* genetic locus (i.e. *r2d2*–/–), and simultaneously carried *tub*-GAL4 driving either UAS-PACT or UAS-*r2d2* (Figure 3A; see Materials and methods for details). These female F1 progeny were then outcrossed to *w*¹¹¹⁸ males to test for fertility; a cross of *w*¹¹¹⁸ females to *w*¹¹¹⁸ males was used as the wild-type control. Eggs resulting from these outcrosses were collected on grape juice agar plates, and allowed to hatch for 24 hours at 25°C. The total number of eggs produced and the number of hatched larva were counted for each cross and hatch rate was calculated as the number of hatched larva divided by the total number of eggs (Figure 3B & 3C). Flies heterozygous for *r2d2* (either *r2d2*¹/+ or Df(2L)BSC142/+) produced eggs and hatch rates equivalent to the wild-type control. Notably, expression of either UAS-PACT or UAS-*r2d2* in *r2d2* heterozygous flies did not influence fertility or hatch rates. Consistent with a previous report²⁷, flies homozygous mutant for *r2d2* had a strong reduction in both the total number of eggs laid and the hatch rate compared to wild-type (Figure 3). We observed a rescue of both total number of eggs ($p=0.0512$) and hatch rate ($p=0.0671$) in *r2d2* mutant flies by ubiquitous (*tub*-GAL4) transgenic expression of UAS-*r2d2* that is approaching statistical significance and consistent with previous reports²⁷. In contrast, ubiquitous expression of UAS-PACT did not suppress the homozygous *r2d2* mutant fertility defects; the hatch rate and number of eggs laid was equivalent to the *r2d2* mutants alone (Figure 3). Despite a documented interaction between PACT and the mammalian small RNA processing machinery and similar domain architecture between these proteins, these results demonstrate that Human PACT is not sufficient to rescue the R2D2 deficient phenotype.

Discussion

Identification of PACT/RAX as a component of the small RNA processing pathway implicates this protein in multiple pathways of post-transcriptional gene regulation through general inhibition of translation by PKR and target-specific regulation by siRNA/miRNA. As such it is important to determine the precise nature of PACT/RAX's involvement in this pathway in order to understand the overall function of PACT/RAX in post-transcriptional gene regulation, and the physiological effects of the protein. Here, we investigated the role of PACT/RAX in RNA silencing by attempting to identify orthologous proteins in *D. melanogaster*. Human PACT was introduced into *Drosophila* to determine whether it could substitute for R2D2, which has a well characterized function in RNA silencing. Expression of PACT was unable to rescue the phenotypes of flies lacking R2D2. These results suggest that the Dicer-associated dsRBPs PACT and R2D2 are not functionally orthologous.

While our study demonstrates that Human PACT cannot substitute for R2D2 function in flies, there are a number of important caveats to the results described here. Despite the lack of rescue, it is nonetheless possible that PACT plays the same (or a similar) role in mammalian cells as R2D2 plays in *Drosophila* cells. One possibility could be that PACT protein is sufficiently different from R2D2 that it cannot interact *in vivo* with *Drosophila* partner proteins that are necessary for R2D2 function. Alternatively, R2D2 may be required to bind specific RNA precursor molecules that PACT is unable to bind (or has a lower affinity for). Investigation of biochemical interactions between PACT and *Drosophila* RNA silencing proteins such as Dicer-1 and Dicer-2 and a biochemical comparison of the specific RNA binding functions of these proteins would begin to address these issues.

In addition to functional discrepancies between these proteins, there may be other potential explanations for these results that would not rule out orthologous function between PACT and R2D2. Although less likely, the lack of PACT rescue of the *r2d2* mutant may be due to inherent difficulty in controlling the tissue-specificity and relative levels of transgene expression *in vivo*. In the case of R2D2, expression in the stalk and follicle cells of the ovary is required for egg development²⁷. Expression of UAS-PACT by *tub*-GAL4 in whole flies was validated by western blot; however, this does not provide information about transgenic expression of PACT in the appropriate tissues. Thus, even though PACT expression was driven by a ubiquitous GAL4 driver we cannot rule out insufficiently high expression of PACT in the relevant cell types. Expression of UAS-R2D2 using the same *tub*-GAL4 driver however rescued the *r2d2* loss-of-function fertility defect. Although this result provides some degree of confidence in the expression levels, the genomic context of the P-element insertion and stability of transgenically-produced RNA and protein can all contribute to expression variability *in vivo*. As such, it still remains a possibility that PACT was not expressed as highly as R2D2 using the same transgenic expression system, and thus PACT may not have rescued fertility due to insufficient expression rather than a lack of orthologous function. Additional experiments investigating tissue-specific expression levels of these proteins as well as using tissue-specific GAL4 drivers would begin to address these concerns.

While the complementation experiments described here indicate that PACT is unable to functionally substitute for R2D2, there are complications to the interpretation of these experiments. Further technical refinements will be necessary to definitively demonstrate or rule out functional orthology between PACT/RAX and R2D2. It also remains a distinct possibility that PACT/RAX is instead orthologous to LOQS, a topic that we are interested in investigating further in the future.

Author contributions

BKD contributed to the conception, design, execution, analysis and interpretation of the experiments detailed in this manuscript, as well as drafting and revising the manuscript. JAM contributed to the conception, design, analysis and interpretation of the experiments detailed in this manuscript, as well as revising the manuscript. GCS contributed to the conception, design, analysis and interpretation of the experiments detailed in this manuscript, as well as revising the manuscript.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by NIH grant CA062220, awarded to G. Sen.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

We wish to thank George Aranjuez for technical assistance with *Drosophila* work.

Supplementary materials

Table S1. Hatch rate and egg count raw data replicate 1.

	Wild type	No transgene		UAS-R2D2		UAS-PACT	
	W1118	+/-	-/-	+/-	-/-	+/-	-/-
Larvae	884	743	153	969	403	728	145
Eggs laid	983	1042	355	1112	631	1021	380
% Hatched	89.92879	71.30518	43.09859	87.14029	63.86688	71.30264	38.15789

Table S2. Hatch rate and egg count raw data replicate 2.

	Wild type	No transgene		UAS-R2D2		UAS-PACT	
	W1118	+/-	-/-	+/-	-/-	+/-	-/-
Larvae	663	651	71	763	579	809	131
Eggs laid	718	785	187	870	721	948	361
% Hatched	92.33983	82.92994	37.96791	87.70115	80.30513	85.33755	36.28809

References

1.

Patel RC, Sen GC: **PACT, a protein activator of the interferon-induced protein kinase, PKR.** *EMBO J.* 1998; **17**(15): 4379–4390.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

2.

Ito T, Yang M, May WS: **RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling.** *J Biol Chem.* 1999; **274**(22): 15427–15432.
[PubMed Abstract](#) | [Publisher Full Text](#)

3.

Bennett RL, Blalock WL, Abtahi DM, et al.: **RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection.** *Blood.* 2006; **108**(3): 821–829.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

4.

Lee ES, Yoon CH, Kim YS, et al.: **The double-strand RNA-dependent protein kinase PKR plays a significant role in a sustained ER stress-induced apoptosis.** *FEBS Lett.* 2007; **581**(22): 4325–4332.
[PubMed Abstract](#) | [Publisher Full Text](#)

5.

Ruvolo PP, Gao F, Blalock WL, et al.: **Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX.** *J Biol Chem.* 2001; **276**(15): 11754–11758.
[PubMed Abstract](#) | [Publisher Full Text](#)

6.

Farrell PJ, Sen GC, Dubois MF, et al.: **Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA.** *Proc Natl Acad Sci U S A.* 1978; **75**(12): 5893–5897.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

7.

Dickerman BK, White CL, Chevalier C, et al.: **Missense mutation in the second RNA binding domain reveals a role for Prkra (PACT/RAX) during skull development.** *PLoS One.* 2011; **6**(12): e28537.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

8.

Rowe TM, Rizzi M, Hirose K, et al.: **A role of the double-stranded RNA-binding protein PACT in mouse ear development and hearing.** *Proc Natl Acad Sci U S A.* 2006; **103**(15): 5823–5828.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

9.

Peters GA, Seachrist DD, Keri RA, et al.: **The double-stranded RNA-binding protein, PACT, is required for postnatal anterior pituitary proliferation.** *Proc Natl Acad Sci U S A.* 2009; **106**(26): 10696–10701.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

10.

Lee Y, Hur I, Park SY, et al.: **The role of PACT in the RNA silencing pathway.** *EMBO J.* 2006; **25**(3): 522–532.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

11. Kok KH, Ng MH, Ching YP, *et al.*: **Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA.** *J Biol Chem.* 2007; **282**(24): 17649–17657.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. van Kouwenhove M, Kedde M, Agami R: **MicroRNA regulation by RNA-binding proteins and its implications for cancer.** *Nat Rev Cancer.* 2011; **11**(9): 644–656.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Czech B, Hannon GJ: **Small RNA sorting: matchmaking for Argonautes.** *Nat Rev Genet.* 2011; **12**(1): 19–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. MacRae IJ, Ma E, Zhou M, *et al.*: **In vitro reconstitution of the human RISC-loading complex.** *Proc Natl Acad Sci U S A.* 2008; **105**(2): 512–517.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Gregory RI, Yan KP, Amuthan G, *et al.*: **The Microprocessor complex mediates the genesis of microRNAs.** *Nature.* 2004; **432**(7014): 235–240.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Tabara H, Yigit E, Siomi H, *et al.*: **The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DEXH-box helicase to direct RNAi in *C. elegans*.** *Cell.* 2002; **109**(7): 861–871.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Saito K, Ishizuka A, Siomi H, *et al.*: **Processing of pre-microRNAs by the Dicer-1-Loquacious complex in *Drosophila* cells.** *PLoS Biol.* 2005; **3**(7): e235.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Liu Q, Rand TA, Kalidas S, *et al.*: **R2D2, a bridge between the initiation and effector steps of the *Drosophila* RNAi pathway.** *Science.* 2003; **301**(5641): 1921–1925.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Laraki G, Clerzius G, Daher A, *et al.*: **Interactions between the double-stranded RNA-binding proteins TRBP and PACT define the Medipal domain that mediates protein-protein interactions.** *RNA Biol.* 2008; **5**(2): 92–103.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Bernstein E, Caudy AA, Hammond SM, *et al.*: **Role for a bidentate ribonuclease in the initiation step of RNA interference.** *Nature.* 2001; **409**(6818): 363–366.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Förstemann K, Tomari Y, Du T, *et al.*: **Normal microRNA maturation and germ-line stem cell maintenance requires Loquacious, a double-stranded RNA-binding domain protein.** *PLoS Biol.* 2005; **3**(7): e236.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Zhou R, Czech B, Brennecke J, *et al.*: **Processing of *Drosophila* endo-siRNAs depends on a specific Loquacious isoform.** *RNA.* 2009; **15**(10): 1886–1895.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Tomari Y, Du T, Zamore PD: **Sorting of *Drosophila* small silencing RNAs.** *Cell.* 2007; **130**(2): 299–308.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Marques JT, Kim K, Wu PH, *et al.*: **Loqs and R2D2 act sequentially in the siRNA pathway in *Drosophila*.** *Nat Struct Mol Biol.* 2010; **17**(1): 24–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Liu X, Jiang F, Kalidas S, *et al.*: **Dicer-2 and R2D2 coordinately bind siRNA to promote assembly of the siRISC complexes.** *RNA.* 2006; **12**(8): 1514–1520.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Park JK, Liu X, Strauss TJ, *et al.*: **The miRNA pathway intrinsically controls self-renewal of *Drosophila* germline stem cells.** *Curr Biol.* 2007; **17**(6): 533–538.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Kalidas S, Sanders C, Ye X, *et al.*: ***Drosophila* R2D2 mediates follicle formation in somatic tissues through interactions with Dicer-1.** *Mech Dev.* 2008; **125**(5–6): 475–485.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Horne-Badovinac S, Bilder D: **Mass Transit: epithelial morphogenesis in the *Drosophila* egg chamber.** *Dev Dyn.* 2005; **232**(3): 559–574.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Marques JT, White CL, Peters GA, *et al.*: **The role of PACT in mediating gene induction, PKR activation and apoptosis in response to diverse stimuli.** *J Interferon Cytokine Res.* 2008; **28**(8): 469–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Greenspan RJ: **Fly pushing: the theory and practice of *Drosophila* genetics,** 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 2004.
[Reference Source](#)
31. Bachmann A, Knust E: **The use of P-element transposons to generate transgenic flies.** *Methods Mol Biol.* 2008; **420**: 61–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Ahern-Djamali SM, Comer AR, Bachmann C, *et al.*: **Mutations in *Drosophila* enabled and rescue by human vasodilator-stimulated phosphoprotein (VASP) indicate important functional roles for Ena/VASP homology domain 1 (EVH1) and EVH2 domains.** *Mol Biol Cell.* 1998; **9**(8): 2157–2171.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Grifoni D, Garoia F, Schimanski CC, *et al.*: **The human protein Hugi-1 substitutes for *Drosophila* lethal giant larvae tumour suppressor function *in vivo*.** *Oncogene.* 2004; **23**(53): 8688–8694.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Ryan EL, DuBoff B, Feany MB, *et al.*: **Mediators of a long-term movement abnormality in a *Drosophila melanogaster* model of classic galactosemia.** *Dis Model Mech.* 2012; **5**(6): 796–803.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Brand AH, Perrimon N: **Targeted gene expression as a means of altering cell fates and generating dominant phenotypes.** *Development.* 1993; **118**(2): 401–415.
[PubMed Abstract](#)
36. Rørth P: **Gal4 in the *Drosophila* female germline.** *Mech Dev.* 1998; **78**(1–2): 113–118.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 18 February 2014

<https://doi.org/10.5256/f1000research.2593.r2387>

© 2014 Corbett A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Anita Corbett

Emory University, Atlanta, GA, USA

The manuscript by Dickerman *et al.* describes an attempt to study the functional conservation of RNA binding proteins implicated in processing of small RNAs and activation of dsRNA-dependent protein kinase (PKR). The work exploits a *Drosophila* model where PKR is not relevant thus allowing focus on the small RNA processing pathways. The approach is logical to try to rescue a fertility phenotype observed for the *Drosophila* protein (R2D2) with transgenic expression of a related human protein, PACT. Unfortunately, the authors were not able to demonstrate rescue and thus are left with a negative result.

The data presented do support the conclusions drawn, that no rescue could be detected. There are a number of caveats for this result as the authors describe in the Discussion.

This is a reasonable contribution to the literature in that it would prevent other researchers from wasting time undertaking the identical experiment. The data presented is robust and convincing.

I would suggest some modifications to the text for clarification:

1. The authors begin by describing both related human proteins, PACT and the isoforms of LOQS. While it is logical to describe the family of proteins, this study actually only analyzes the PACT protein. This point should be clearly communicated earlier in the Introduction to the study not just as the final sentence of the Introduction.
2. The section in the Introduction describing Figure 1 is very convoluted and really could be rewritten to be clearer. An example with grammatical errors is the second sentence of this paragraph, which reads: "*The dsRNA binding proteins LOQS and R2D2 bind Dicer-1 to Dicer-2 respectively.*" I think what the authors mean to say is: "*The dsRNA binding proteins, LOQS and R2D2, bind TO Dicer-1 AND Dicer-2, respectively.*"

The description of the proteins really needs to be rewritten for clarification.

3. If the authors could perform an additional experiment to address one of the caveats that they mention, ideally they could compare the expression levels for the transgenic human and fly proteins. Such a direct comparison would really only be possible if the proteins are tagged with an epitope tag.

Given the number of caveats for the study presented here, the real value as described above is simply to communicate that these experiments have been attempted using this approach.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 03 Apr 2014

Benjamin Dickerman, Cleveland Clinic, Cleveland, OH, USA

We have addressed the comments presented in a revised manuscript. A sentence reading "*To this end, we investigated the functional orthology between PACT and the Drosophila melanogaster dsRBP R2D2.*" has been added to the end of the first paragraph of the introduction, to highlight the focus of this manuscript before describing the family of dsRBPs. The paragraph describing figure 1 has been reordered and edited for clarity, and to address the specific grammatical error mentioned by the reviewer. A sentence reading "*This issue could be addressed in future experiments by expressing epitope-tagged R2D2 or PACT in r2d2 mutant flies to correlate rescue of the r2d2 deficient phenotype with a direct comparison of protein expression level.*" has been added to the relevant paragraph of the discussion section suggesting this experiment as part of future studies. This has been referenced as a comment by the reviewer to credit the suggestion.

Competing Interests: No competing interests were disclosed.

Reviewer Report 06 December 2013

<https://doi.org/10.5256/f1000research.2593.r2676>

© 2013 Sadler A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Anthony Sadler

Monash Institute for Medical Research, Monash University, Melbourne, Australia

This is a useful study that is well executed and that makes a valuable contribution. The results are clearly described. An attempt to address the acknowledged uncertainties in this study, by measuring the levels of PACT in the critical tissues, comparison of the levels of expression of PACT to the transgenic R2D2, detecting an association between human PACT and Drosophila Dicer-2,

and/or otherwise confirming function of the PACT transgene would have increased confidence in the conclusion. These measures would be less germane if the parallel experiment to rescue the function of *Drosophila* LOQS, which is the more likely homolog for PACT, had demonstrated the functionality of the PACT transgene. Perhaps a sentence could be introduced into the discussion that these separate experiments validated the PACT transgene functioned in *Drosophila* - if this was the case.

I have a number of very minor criticisms that might improve the manuscript.

The statement in the abstract that the primary function of PACT is to activate PKR is not accurate. As the authors themselves state the relative physiological consequence of PACT, in small RNA biogenesis or protein translation, is uncertain. This sentence might be better expressed by, for instance, writing PACT was first described to function by activating PKR.

The sentence in the abstract stating that additional models are required to clarify the function of PACT does not best justify the study approach. Alternatively, describing the utility of *Drosophila* to decipher small RNA biogenesis would seem more appropriate.

It might improve the clarity of the text if the authors selected a simpler abbreviation, rather than PACT/RAX, such as either PACT or RAX.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 03 Apr 2014

Benjamin Dickerman, Cleveland Clinic, Cleveland, OH, USA

We agree that inclusion of LOQS rescue data would strengthen the arguments presented in this manuscript. Despite repeated efforts, and likely due to technical limitations, *Drosophila* LOQS (UAS-LOQS-PB) was unable to rescue *loqs* loss-of-function mutations in our hands. This important control has been previously reported (Park *et al.*, 2007) to be sufficient to rescue the *loqs* loss-of-function mutation that was used in this study. Because these rescue studies were inconclusive, we are currently unable to confirm that LOQS and PACT are functional orthologous.

We have addressed the remaining comments presented here in a revised manuscript. The abstract has been revised to clarify stress-induced PKR activation as the first described rather than the primary function of PACT, as well as to highlight the genetic utility of *Drosophila* as a model system, rather than merely suggesting that additional model systems are required. To address the final comment regarding PACT nomenclature, the manuscript has been revised for clarity by changing PACT/RAX to PACT unless specifically referring to the mouse protein RAX.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research